To explore new protective measure against visceral leishmaniasis, reverse vaccinology approach was employed to identify key immunogenic regions which can mediate long-term immunity. In-depth computational analysis revealed nine promiscuous epitopes which can possibly be presented by 46 human leukocyte antigen, thereby broadening the worldwide population up to 94.16%. This is of reasonable significance that most of the epitopes shared 100% sequence homology with other Leishmania species and could evoke a common pattern of protective immune response. Transporter associated with antigen processing binding affinity, molecular docking approach followed by dynamics simulation and human leukocyte antigen stabilization assay suggested that the best five optimal set of epitopes bind in between α1 and α2 binding groove with sufficient affinity and stability which allows the translocation of intact epitope to the cell surface. Fascinatingly, the human leukocyte antigen stabilization assay exhibited a modest correlation with the positive immunogenicity score predicted by class I pMHC immunogenicity predictor. A support for this notion came from ELISA and FACS analysis where the epitopes as a cocktail induced CD8+ IFN-γ and Granzyme B levels significantly in treated visceral leishmaniasis subject which suggests the immunogenic ability of the selected epitopes.
The potential HLA Class I-restricted epitopes derived from LeIF and TSA of Leishmania donovani evoke anti-leishmania CD8+ T lymphocyte response.
源自杜氏利什曼原虫 LeIF 和 TSA 的潜在 HLA I 类限制性表位可诱发抗利什曼原虫 CD8+ T 淋巴细胞反应
阅读:4
作者:Dikhit Manas Ranjan, Das Sushmita, Mahantesh Vijaya, Kumar Akhilesh, Singh Ashish Kumar, Dehury Budheswar, Rout Ajaya Kumar, Ali Vahab, Sahoo Ganesh Chandra, Topno Roshan Kamal, Pandey Krishna, Das V N R, Bimal Sanjiva, Das Pradeep
| 期刊: | Scientific Reports | 影响因子: | 3.900 |
| 时间: | 2018 | 起止号: | 2018 Sep 21; 8(1):14175 |
| doi: | 10.1038/s41598-018-32040-x | 研究方向: | 细胞生物学 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
